Company intelligence / Profile preview

Altropus

Dallas, Texas, United States

Ownership: Private
Development stage: Other

Overview

Altropus is a biotechnology company focused on developing novel therapeutics that target the Low-density lipoprotein receptor-related protein 1 (LRP1) pathway. Founded by prominent researchers from UT Southwestern Medical Center, the company leverages deep expertise in endocytosis and cellular signaling to address diseases of aging and cellular dysfunction. Their research primarily targets neurodegenerative conditions like Alzheimer's disease, as well as cardiovascular disorders and fibrotic diseases. By modulating LRP1 activity, Altropus aims to restore tissue homeostasis and physiological balance in patients with high unmet medical needs. The company operates as a research-driven entity backed by leading life science venture capital firms.

Therapeutic areas: CardiovascularNeurologyOther
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Altropus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altropus.

Explore the full profile